Perphenazine

Summary

Perphenazine (CHEMBL567) is an approved small-molecule phenothiazine antipsychotic drug (ATC N05AB03) targeting HTR6, HTR7, and DRD2; indicated across 9 conditions including psychotic disorder and anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AB03
• Targets: 6 (HTR6, HTR7, DRD2…)
• Indications: 9 conditions
• Clinical trials: 17
• Chemistry: 404 Da · C21H26ClN3OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL567
Name	Perphenazine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4748
ChEBI	CHEBI:8028
ATC	N05AB03
Molecular formula	C21H26ClN3OS
Molecular weight	404
InChIKey	RGCVKNLCSQQDEP-UHFFFAOYSA-N

SMILES: C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO

IUPAC name: 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol

ChEBI definition: A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug, dopaminergic antagonist, antiemetic.

Also known as: Chlorpiprazine, Decentan, Fentazin, NSC-150866, Perfenazina, Perphenazine, Perphenazine component of etrafon-a, Perphenazine maleate, Trilafon, Trilafon-la, perphenazine, SID11111645

Patent coverage: 5,954 distinct patent families (21,883 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 21,767 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HTR6	5-HT6 receptor	Inverse agonist	7.1	0.2%	P50406
HTR7	5-HT7 receptor	Inverse agonist	7.2	0.8%	P34969
DRD2	D2 receptor	Antagonist	9.59	0%	P14416
HRH1	H1 receptor	Antagonist	8.1	0%	P35367
HTR2A	5-HT2A receptor	Antagonist	8.2	0%	P28223
HTR2C	5-HT2C receptor	Antagonist	6.9	0%	P28335

Broader ChEMBL bioactivity targets: 66 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, ATP-dependent DNA helicase Q1, 4’-phosphopantetheinyl transferase ffp, Thrombopoietin, G-protein coupled receptor 35, NPC intracellular cholesterol transporter 1, Geminin, Endonuclease 4, Ras-related protein Rab-9A, Peripheral myelin protein 22, Apelin receptor, Aldehyde oxidase 1, Aldehyde oxidase 1, Aldehyde oxidase 1, Pleiotropic ABC efflux transporter of multiple drugs.

Bioactivity

ChEMBL activities: 55 potent at pChembl ≥ 5 of 100 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
DRD2	9.52	IC50	0.3	nM	CHEMBL_ACT_13317546
DRD2	7.77	AC50	17	nM	CHEMBL_ACT_25140031
HTR2A	7.68	AC50	20.7	nM	CHEMBL_ACT_25173514
HTR7	7.64	Ki	23	nM	CHEMBL_ACT_82695
ADRA1A	7.59	AC50	25.8	nM	CHEMBL_ACT_25137757
CYP2D6	7.5	Potency	31.6	nM	CHEMBL_ACT_4969903
CYP2D6	7.5	AC50	31.62	nM	CHEMBL_ACT_6067267
AOX1	7.48	IC50	33	nM	CHEMBL_ACT_5102808
DRD3	7.41	AC50	39	nM	CHEMBL_ACT_25193233
HRH1	7.38	AC50	42	nM	CHEMBL_ACT_25212207
CYP2D6	6.92	IC50	120	nM	CHEMBL_ACT_15450962
ADRA2B	6.85	AC50	140	nM	CHEMBL_ACT_25143408
CYP2D6	6.7	Potency	199.5	nM	CHEMBL_ACT_4949755
CYP1A2	6.5	AC50	316.2	nM	CHEMBL_ACT_6059963
SMN1	6.4	Potency	398.1	nM	CHEMBL_ACT_3886126
ADRA2C	6.34	AC50	460	nM	CHEMBL_ACT_25147574
ALDH1A1	6.28	IC50	524.2	nM	CHEMBL_ACT_24348830
HTR2A	6.24	AC50	570	nM	CHEMBL_ACT_25224899
TDP1	6.15	Potency	707.9	nM	CHEMBL_ACT_3934608
Q9Z0U5	6.13	IC50	740	nM	CHEMBL_ACT_5102821
HTR2B	6.11	AC50	770	nM	CHEMBL_ACT_25227247
KCNH2	6.05	AC50	900	nM	CHEMBL_ACT_25117417
OPRK1	5.98	AC50	1045	nM	CHEMBL_ACT_25129158
P33302	5.85	IC50	1400	nM	CHEMBL_ACT_5306636
CYP3A4	5.6	Potency	2512	nM	CHEMBL_ACT_4957349
CYP3A4	5.6	Potency	2512	nM	CHEMBL_ACT_5026706
HTR1A	5.57	AC50	2700	nM	CHEMBL_ACT_25215809
ADRA2A	5.56	IC50	2775	nM	CHEMBL_ACT_25751424
ADRB2	5.56	IC50	2777	nM	CHEMBL_ACT_25751425
SMN1	5.55	Potency	2818	nM	CHEMBL_ACT_3892312
SLC6A4	5.54	AC50	2900	nM	CHEMBL_ACT_25150045
CX3CR1	5.53	IC50	2949	nM	CHEMBL_ACT_25751427
CYP2C19	5.5	Potency	3162	nM	CHEMBL_ACT_4015608
APLNR	5.49	IC50	3218	nM	CHEMBL_ACT_25751426
KCNH2	5.46	Ki	3454	nM	CHEMBL_ACT_7736473
HTR2C	5.44	AC50	3600	nM	CHEMBL_ACT_25131515
Q5FB27	5.44	IC50	3600	nM	CHEMBL_ACT_5102838
GLP1R	5.41	IC50	3931	nM	CHEMBL_ACT_25751430
GPR65	5.4	IC50	3944	nM	CHEMBL_ACT_25751434
GPR183	5.38	IC50	4172	nM	CHEMBL_ACT_25751432
KCNH2	5.38	IC50	4216	nM	CHEMBL_ACT_7736472
CYP1A2	5.35	IC50	4490	nM	CHEMBL_ACT_15449393
FPR1	5.32	IC50	4803	nM	CHEMBL_ACT_25751428
GPR119	5.29	IC50	5165	nM	CHEMBL_ACT_25751431
GPR35	5.22	IC50	5967	nM	CHEMBL_ACT_25751433
FPR3	5.21	IC50	6243	nM	CHEMBL_ACT_25751429
O54754	5.21	IC50	6100	nM	CHEMBL_ACT_5102814
P0A6C1	5.2	Potency	6310	nM	CHEMBL_ACT_4069460
SLC6A3	5.19	AC50	6500	nM	CHEMBL_ACT_25123653
TDP1	5.15	Potency	7080	nM	CHEMBL_ACT_3927968
MTOR	5.13	Potency	7362	nM	CHEMBL_ACT_4522781
MAPT	5.05	Potency	8912	nM	CHEMBL_ACT_3967446
MAPT	5.05	Potency	8912	nM	CHEMBL_ACT_3972097
TP53	5	Potency	10000	nM	CHEMBL_ACT_4870157
NPSR1	5	Potency	10000	nM	CHEMBL_ACT_4884944

Target pathways

Aggregated over 6 target gene(s): HTR6, HTR7, DRD2, HRH1, HTR2A, HTR2C.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	4	HTR2A, HTR2C, HTR6, HTR7
Signaling by GPCR	4	HTR2A, HTR2C, HTR6, HTR7
Class A/1 (Rhodopsin-like receptors)	4	HTR2A, HTR2C, HTR6, HTR7
Amine ligand-binding receptors	4	HTR2A, HTR2C, HTR6, HTR7
GPCR downstream signalling	4	HTR2A, HTR2C, HTR6, HTR7
Serotonin receptors	4	HTR2A, HTR2C, HTR6, HTR7
GPCR ligand binding	4	HTR2A, HTR2C, HTR6, HTR7
G alpha (q) signalling events	3	HRH1, HTR2A, HTR2C
G alpha (s) signalling events	2	HTR6, HTR7
Histamine receptors	1	HRH1
Dopamine receptors	1	DRD2
RHOBTB3 ATPase cycle	1	HTR7

Dominant GO biological processes

GO term	Targets
signal transduction	6
G protein-coupled receptor signaling pathway	6
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	5
chemical synaptic transmission	5
G protein-coupled serotonin receptor signaling pathway	4
intracellular calcium ion homeostasis	3
phospholipase C-activating G protein-coupled receptor signaling pathway	3
release of sequestered calcium ion into cytosol	3
positive regulation of ERK1 and ERK2 cascade	3
phospholipase C-activating serotonin receptor signaling pathway	3
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	2
adenylate cyclase-activating serotonin receptor signaling pathway	2
temperature homeostasis	2
locomotory behavior	2
visual learning	2

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050
cocaine dependence	2	MONDO:0005186	EFO:0002610

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	6
PHASE3	4
Not specified	3
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00802100	PHASE4	COMPLETED	Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
NCT01157351	PHASE4	COMPLETED	15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
NCT01193166	PHASE4	WITHDRAWN	Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
NCT02199743	PHASE4	COMPLETED	Lurasidone Effects on Tissue Glutamate in Schizophrenia
NCT02307396	PHASE4	COMPLETED	Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
NCT00009204	PHASE3	COMPLETED	Serotonergic Pharmacotherapy for Agitation of Dementia
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT02431702	PHASE3	COMPLETED	A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant’s With Recent-onset Schizophrenia or Schizophreniform
NCT04606264	PHASE3	COMPLETED	Recommendations of Enhanced Recovery Interventions for Patient’s Clinical Team and Collection of Associated Data
NCT00737256	PHASE2	UNKNOWN	A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
NCT05762146	PHASE2	UNKNOWN	Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
NCT00480246	PHASE1	COMPLETED	A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer
NCT04776499	PHASE1	COMPLETED	Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers
NCT02600741	Not specified	COMPLETED	Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
NCT02893371	Not specified	TERMINATED	Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
NCT03019887	Not specified	COMPLETED	Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 26 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

607 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
BREXPIPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
CLOZAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
DOXEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
HALOPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
IMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
KETANSERIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
KETOTIFEN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
LOXAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
METHYSERGIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
MIANSERIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
NEFAZODONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
OLANZAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
PROMAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
QUETIAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
RISPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
THIORIDAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
THIOTHIXENE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
LATREPIRDINE	ChEMBL	Phase 3	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
FANANSERIN	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
LYSERGIDE	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
MARITUPIRDINE	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
METERGOLINE	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
PENFLURIDOL	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
RITANSERIN	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
SPIPERONE	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
Pyrazinamide	PubChem	Approved	DRD2, HRH1, HTR2A, HTR2C, HTR6, HTR7
DESLORATADINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
PALIPERIDONE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR7
AMIODARONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
ASENAPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
BENZTROPINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
BUSPIRONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR7
CARVEDILOL	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6, HTR7
CISAPRIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR7
CLEMASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
DIBENZEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR6, HTR7
EBASTINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
FLUOXETINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
HYDROXYZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR6, HTR7
ILOPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
IPRINDOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
LURASIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR7
MAPROTILINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
METHYLERGONOVINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
NORTRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
PERGOLIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
PIMOZIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
PIPAMAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
PROCHLORPERAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
PROMETHAZINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
SERTINDOLE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
SUNITINIB	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
TEGASEROD	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6, HTR7
TERFENADINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C, HTR6
IDALOPIRDINE	ChEMBL	Phase 3	DRD2, HTR2A, HTR2C, HTR6, HTR7
LISURIDE	ChEMBL	Phase 3	DRD2, HRH1, HTR2A, HTR2C, HTR6
ZUCLOPENTHIXOL	ChEMBL	Phase 3	DRD2, HRH1, HTR2A, HTR2C, HTR6
NIGULDIPINE	ChEMBL	Phase 2	DRD2, HRH1, HTR2C, HTR6, HTR7
PIZOTYLINE	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR2C, HTR7
SPIRAMIDE	ChEMBL	Phase 2	DRD2, HRH1, HTR2A, HTR6, HTR7
Fidaxomicin	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
PRAMIPEXOLE	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR7
Propoxyphene	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
TAMSULOSIN	ChEMBL + PubChem	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR7
AMISULPRIDE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR7
AMLODIPINE	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6
APOMORPHINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
AZATADINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
BENPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6
BUTRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
DESIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
DICYCLOMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR2A, HTR2C, HTR6
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6
DIPHENHYDRAMINE	ChEMBL	Phase 4 (approved)	HRH1, HTR2A, HTR2C, HTR6
DOMPERIDONE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
DOTHIEPIN	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
DROPERIDOL	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
DULOXETINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
ECONAZOLE	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6
ERGOTAMINE	ChEMBL	Phase 4 (approved)	DRD2, HTR2A, HTR2C, HTR6
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	DRD2, HRH1, HTR2A, HTR2C
MEPAZINE	ChEMBL	Phase 4 (approved)	HRH1, HTR2A, HTR2C, HTR6